Damora Therapeutics, Inc. (DMRA) Balance Sheet
As of 2026-06-30 (10-Q), Damora Therapeutics, Inc. (DMRA) reported total assets of $543.6M, total liabilities of $27.6M and shareholders' equity of $516.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $540.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DMRADamora Therapeutics, Inc.Follow DMRA — free
—
Price chart with a free account
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 163.6 | 62.6 | 32.8 | 21.5 | 14.2 | 257.6 | 540.5 | |
| Short-term investments | — | 37.6 | 27.4 | 11.7 | — | — | — | |
| Current assets | 169.3 | 110.1 | 63.9 | 36.8 | 16.8 | 260.4 | 543.6 | |
| Total assets | 171.6 | 122.2 | 73.2 | 38.2 | 17.1 | 260.5 | 543.6 | |
| Current liabilities | 5.6 | 4.5 | 11.1 | 5.8 | 1.2 | 20.1 | 27.6 | |
| Total liabilities | 6.1 | 5.0 | 11.4 | 5.9 | 1.3 | 20.1 | 27.6 | |
| Shareholders' equity | 165.5 | 117.2 | 61.8 | 32.3 | 15.8 | 240.4 | 516.1 |
USD millions · SEC XBRL
Damora Therapeutics, Inc. — questions
- How much cash does Damora Therapeutics, Inc. have?
- $540.5M in cash and cash equivalents as of 2026-06-30.
- What are Damora Therapeutics, Inc.'s total assets?
- $543.6M as of 2026-06-30.
- What is Damora Therapeutics, Inc.'s shareholders' equity?
- $516.1M as of 2026-06-30.
Every figure on this page comes from Damora Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.